Filing Details

Accession Number:
0001209191-21-030304
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-05 13:00:00
Reporting Period:
2021-05-03
Accepted Time:
2021-05-05 16:14:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1437435 Marc Tessier-Lavigne C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-05-03 3,139 $60.08 2,589,157 No 4 S Direct
Common Stock Disposition 2021-05-03 98 $61.20 2,589,059 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Includes 3,253 restricted stock units.